Ipamorelin
Ipamorelin is a growth hormone secretagogue that acts at the ghrelin receptor. That makes it mechanically distinct from the GHRH analogues it is usually listed alongside — sermorelin, CJC-1295 and tesamorelin all act on a different receptor.
It is commonly described as selective, meaning it is characterised as engaging that pathway without the broader hormonal effects seen with some earlier secretagogues.
- TypeGhrelin receptor agonist
- NotA GHRH analogue
- US statusNot FDA-approved
- CompoundingFDA safety-concern category
The pathway it acts on
Ghrelin is best known as a hunger signal, but its receptor also feeds into pituitary growth hormone signalling. Ipamorelin engages that receptor — a separate route from the GHRH pathway.
This is why ipamorelin and a GHRH analogue are sometimes discussed together: they approach the same downstream system from two directions. Whether combining them is sensible is a clinical question, not a settled one.
Most of what circulates about this compound comes from preclinical work — cell and animal models. What research explores in that setting does not transfer automatically to people, and the gap between a promising animal result and an established human option is where almost all of the marketing in this category lives.
Regulatory position
Ipamorelin has no US approval. The FDA has placed it in the category of bulk substances raising significant safety concerns for use in compounding, which meaningfully constrains lawful preparation by a compounding pharmacy.
That matters when a clinic offers it. A provider supplying ipamorelin should be able to explain precisely what they are supplying and on what basis.
It is prohibited in competitive sport under WADA's rules for this class.
Where it comes from, and why that matters
Material sold online is generally offered as a research chemical for laboratory use. That is not a formality. It means the vial was not prepared to pharmaceutical manufacturing standards, was not tested for identity and purity the way a prescription medicine is, and was not intended to be put into a person.
Independent testing of this market has repeatedly found products that do not match their labels — wrong quantity, wrong substance, or contaminants. You cannot assess any of that by looking at the vial.
A compounding pharmacy working on a prescriber's order is a different situation with real oversight attached. If someone is offering you a compounded preparation, ask which pharmacy, in which state, and under what authority for this specific substance.
How to approach it
Start from the symptom, not the compound. Ask what will be measured, what the finding would need to be to justify anything, and what happens if the measurements come back unremarkable.
Dosing is determined by a licensed provider.
Questions
Ipamorelin: common questions
- What is ipamorelin?
- A growth hormone secretagogue acting at the ghrelin receptor, distinct from GHRH analogues such as sermorelin and CJC-1295.
- Is ipamorelin FDA-approved?
- No. It has also been placed in the FDA category of bulk substances raising significant safety concerns for compounding.
- How is it different from sermorelin?
- Different receptor. Sermorelin is a GHRH analogue; ipamorelin acts at the ghrelin receptor. They reach the same downstream system by different routes.
- Is it prohibited in sport?
- Yes, under the WADA list covering peptide hormones and growth factors.
Talk to a licensed provider before considering any of this
Peptides are prescriber territory, and the useful first step is finding out what is actually going on rather than picking a compound. We connect you with licensed providers who investigate first.
Find a licensed providerMedical disclaimer
TreatRadar is an information and referral service. We are not a medical provider, we do not practise medicine, and nothing here is medical advice, diagnosis, or a treatment recommendation. Decisions about treatment belong to you and a licensed clinician who knows your history.
We may be compensated when you connect with a provider through this site. That never changes which providers we list or how we describe them — how we verify providers.
Some information (pricing, provider coverage, state rules) may change or await verification — confirm details directly with the provider or the relevant state medical board before booking.